Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

Neurobiology of Aging

Volumn 28, Issue 4, 2007, Pages 568-578

  Kashani, Alireza ^a   Betancur, Catalina ^a   Giros, Bruno ^a   Hirsch, Etienne ^b   Mestikawy, Salah El ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Human; Immunoautoradiography; Parkinson disease; Prefrontal cortex; Putamen; Temporal cortex; Vesicular glutamate transporter; VGLUT1; VGLUT2; Western blot

Indexed keywords

GLUTAMIC ACID; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; VESICULAR GLUTAMATE TRANSPORTER 3;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MALE; NEUROPATHOLOGY; NEUROTRANSMISSION; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PUTAMEN; TEMPORAL CORTEX; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BLOTTING, WESTERN; BRAIN; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POSTMORTEM CHANGES; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1; VESICULAR GLUTAMATE TRANSPORT PROTEIN 2;

EID: 33847135804     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.02.010     Document Type: Article

References (56)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60 (2003) 387-392
2. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
3. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989) 366-375
4. Anglade P., Mouatt-Prigent A., Agid Y., and Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 5 (1996) 121-128
5. Bellocchio E.E., Reimer R.J., Fremeau Jr. R.T., and Edwards R.H. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289 (2000) 957-960
6. Bellocchio E.E., Hu H., Pohorille A., Chan J., Pickel V.M., and Edwards R.H. The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J Neurosci 18 (1998) 8648-8659
7. Calabresi P., Mercuri N.B., Sancesario G., and Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116 (1993) 433-452
8. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 19 (1996) 19-24
9. Carlsson M., and Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75 (1989) 221-226
10. Centonze D., Calabresi P., Giacomini P., and Bernardi G. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin Neurophysiol 110 (1999) 2006-2013
11. Cummings J.L. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1 (1988) 24-36
12. Daniels R.W., Collins C.A., Gelfand M.V., Dant J., Brooks E.S., Krantz D.E., et al. Increased expression of the drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. J Neurosci 24 (2004) 10466-10474
13. Defebvre L., Lecouffe P., Destee A., Houdart P., and Steinling M. Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease. Acta Neurol Scand 92 (1995) 235-241
14. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 (1990) 281-285
15. Drouot X., Oshino S., Jarraya B., Besret L., Kishima H., Remy P., et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 44 (2004) 769-778
16. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57 (2000) 342-352
17. Eberling J.L., Richardson B.C., Reed B.R., Wolfe N., and Jagust W.J. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 15 (1994) 329-335
18. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14 (1994) 783-801
19. Emre M. What causes mental dysfunction in Parkinson's disease?. Mov Disord 18 Suppl. 6 (2003) S63-S71
20. Engber T.M., Papa S.M., Boldry R.C., and Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5 (1994) 2586-2588
21. Fremeau Jr. R.T., Voglmaier S., Seal R.P., and Edwards R.H. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci 27 (2004) 98-103
22. Fremeau Jr. R.T., Kam K., Qureshi T., Johnson J., Copenhagen D.R., Storm-Mathisen J., et al. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304 (2004) 1815-1819
23. Fremeau Jr. R.T., Troyer M.D., Pahner I., Nygaard G.O., Tran C.H., Reimer R.J., et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron 31 (2001) 247-260
24. Girault J.A., Raisman-Vozari R., Agid Y., and Greengard P. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. Proc Natl Acad Sci USA 86 (1989) 2493-2497
25. Gras C., Herzog E., Bellenchi G.C., Bernard V., Ravassard P., Pohl M., et al. A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci 22 (2002) 5442-5451
26. Henderson J.M., Carpenter K., Cartwright H., and Halliday G.M. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123 (2000) 1410-1421
27. Henderson J.M., Carpenter K., Cartwright H., and Halliday G.M. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 47 (2000) 345-352
28. Herzog E., Gilchrist J., Gras C., Muzerelle A., Ravassard P., Giros B., et al. Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain. Neuroscience 123 (2004) 983-1002
29. Herzog E., Bellenchi G.C., Gras C., Bernard V., Ravassard P., Bedet C., et al. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J Neurosci 21 (2001) RC181
30. Hirsch E.C., Perier C., Orieux G., Francois C., Feger J., Yelnik J., et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 23 (2000) S78-S85
31. Hu M.T., Taylor-Robinson S.D., Chaudhuri K.R., Bell J.D., Labbe C., Cunningham V.J., et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123 (2000) 340-352
32. Imon Y., Matsuda H., Ogawa M., Kogure D., and Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 40 (1999) 1583-1589
33. Kaneko T., and Fujiyama F. Complementary distribution of vesicular glutamate transporters in the central nervous system. Neurosci Res 42 (2002) 243-250
34. Kaneko T., Fujiyama F., and Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J Comp Neurol 444 (2002) 39-62
35. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res 318 (2004) 115-120
36. Klockgether T., and Turski L. NMDA antagonists potentiate antiparkinsonian actions of l-Dopa in monoamine-depleted rats. Ann Neurol 28 (1990) 539-546
37. Lange K.W., Kornhuber J., and Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21 (1997) 393-400
38. Lees A.J., and Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 106 (1983) 257-270
39. Lindefors N., and Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 115 (1990) 248-252
40. Loschmann P.A., Lange K.W., Kunow M., Rettig K.J., Jahnig P., Honore T., et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-Dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 3 (1991) 203-213
41. Martin-Ruiz C.M., Piggott M., Gotti C., Lindstrom J., Mendelow A.D., Siddique M.S., et al. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology 39 (2000) 2830-2839
42. Meshul C.K., Cogen J.P., Cheng H.W., Moore C., Krentz L., and McNeill T.H. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway. Exp Neurol 165 (2000) 191-206
43. Ni B., Wu X., Yan G.M., Wang J., and Paul S.M. Regional expression and cellular localization of the Na(+)-dependent inorganic phosphate cotransporter of rat brain. J Neurosci 15 (1995) 5789-5799
44. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67 (2002) 53-83
45. Orieux G., Francois C., Feger J., Yelnik J., Vila M., Ruberg M., et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97 (2000) 79-88
46. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115 Pt 6 (1992) 1727-1751
47. Papa S.M., and Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39 (1996) 574-578
48. Sadikot A.F., Parent A., and Francois C. The centre median and parafascicular thalamic nuclei project respectively to the sensorimotor and associative-limbic striatal territories in the squirrel monkey. Brain Res 510 (1990) 161-165
49. Sidibe M., and Smith Y. Thalamic inputs to striatal interneurons in monkeys: synaptic organization and co-localization of calcium binding proteins. Neuroscience 89 (1999) 1189-1208
50. Smith A.D., and Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13 (1990) 259-265
51. Smith Y., Raju D.V., Pare J.F., and Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 27 (2004) 520-527
52. Takamori S., Rhee J.S., Rosenmund C., and Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 407 (2000) 189-194
53. Takamori S., Rhee J.S., Rosenmund C., and Jahn R. Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). J Neurosci 21 (2001) RC182
54. Varoqui H., Schafer M.K., Zhu H., Weihe E., and Erickson J.D. Identification of the differentiation-associated Na +/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J Neurosci 22 (2002) 142-155
55. Wilson N.R., Kang J., Hueske E.V., Leung T., Varoqui H., Murnick J.G., et al. Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. J Neurosci 25 (2005) 6221-6234
56. Wojcik S.M., Rhee J.S., Herzog E., Sigler A., Jahn R., Takamori S., et al. An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci USA 101 (2004) 7158-7163. [Epub 2004 April 21]